Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07449702 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Oruka Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 6
- Study locations
NCT07449702: Recruiting Phase 2 study of Plaque Psoriasis, sponsored by Oruka Therapeutics.
NCT07449702 is a Phase 2 study of Plaque Psoriasis that is actively recruiting participants, run by Oruka Therapeutics. The registered enrollment target is 80 participants, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (81% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07449702, a Phase 2 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Oruka Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 6
- Study locations
Study Summary
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Primary Outcome
Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.
Conditions Studied
Interventions
- DRUG ORKA-001
Study Locations (6)
California
- Oruka Therapeutics Investigative Site - Los Angeles
- Oruka Therapeutics Investigative Site - San Diego
Florida
- Oruka Therapeutics Investigative Site - Coral Gables
Kentucky
- Oruka Therapeutics Investigative Site - Bowling Green
Maryland
- Oruka Therapeutics Investigative Site - Rockville
Ontario
- Oruka Therapeutics Investigative Site - Peterborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
What NCT07449702 shows while recruiting
NCT07449702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ORKA-001 is the first listed.
NCT07449702 lists 6 locations in 5 states (California, Florida, Kentucky).
Frequently Asked Questions
What is clinical trial NCT07449702 about?
NCT07449702 is a clinical study titled "An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis". An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
What is the current status of trial NCT07449702?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-02-23. Estimated completion is 2029-01.
What conditions does trial NCT07449702 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT07449702?
The interventions under investigation include: ORKA-001 (DRUG).
Who is sponsoring clinical trial NCT07449702?
This trial is sponsored by Oruka Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07449702 being conducted?
This trial has 6 study locations across California, Florida, Kentucky, Maryland, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07449702's enrollment target sits among peer trials
80 33rd of 45 higher than 12 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
-
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI